NCT06639711

Taurine Eye Drops May Prevent the Progression of Cataract

Taurine Affects the Progression of Senile Cataract: a Single-arm Pre-post Intervention Study

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: University Of Anbar · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract. This study could answer: * Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract? * The acceptance/ compliance of participants to taurine-containing eye drops. * Could long-term use of taurine-containing eye drops cause adverse effect(s)? Participants will: * Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year. * Visit eye clinic every 3 months for assessment and visual examination. * Keep notes for their symptoms and their adherence to treatment.

Conditions

• Cataract

Interventions

Type	Name	Description
DRUG	Taurine	Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year

Timeline

• Start date: 2023-07-10
• Primary completion: 2024-12-20
• Completion: 2024-12-20
• First posted: 2024-10-15
• Last updated: 2024-12-09

Locations

1 site across 1 country: Iraq